LICENSE AGREEMENT for MSK’s technology “CD33 Antibodies and constructs thereof” between MEMORIAL SLOAN KETTERING CANCER CENTER and Y-MABS THERAPEUTICS, INC. Dated: November 10, 2017License Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
This Agreement (the “Agreement”) is effective on the date of the last signature below (“Effective Date”), and is by and between Memorial Sloan Kettering Cancer Center (“MSK”), a New York not-for-profit corporation with its principal office at 1275 York Avenue, New York, NY, and Y-mAbs Therapeutics, Inc., a Delaware corporation with its principal office at 750 3rd Avenue, New York, N.Y. 10017 (“LICENSEE”). MSK and LICENSEE are sometimes referred to singly as “Party” and collectively as “Parties”.
SERVICE AGREEMENT BETWEEN Y-MABS THERAPEUTICS A/S AND BO KRUSEService Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations
MASTER DATA SERVICES AGREEMENTMaster Data Services Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
This MASTER DATA SERVICES AGREEMENT (together with Appendix A and any Project Descriptions (as defined in Section 1), the “Agreement”) is made on September 20, 2016 (the “Effective Date”) by and between YMABS THERAPEUTICS, INC., a for profit having a place of business at 701 Gateway Drive, Suite 200, South San Francisco, Ca 94080 (“Ymabs”) and MEMORIAL SLOAN KETTERING CANCER CENTER, a New York membership corporation with principal offices at 1275 York Avenue, New York, New York 10065 (“Institution”).
Exhibit D SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
This Sponsored Research Agreement (this “Agreement”), effective as of the date of the signature of the underlying license agreement, SK2017-1696, dated November 13, 2017, (“Effective Date”), is between Memorial Sloan Kettering Cancer Center, a New York not-for-profit entity, with offices at 1275 York Avenue, New York, NY 10065 (“MSK”) and Y-mAbs Therapeutics, Inc., a Delaware corporation with a principal office at 750 3rd Avenue. New York, N.Y. 10017 (“Sponsor”). MSK and Sponsor may be individually referred to as a “Party”, and collectively as the “Parties”. This Exhibit D, including Appendix A and Appendix B attached hereto, replaces the Exhibit D (including Appendix B) of the License Agreement for MSK’s technology “CD33 Antibodies and constructs thereof” between Memorial Sloan Kettering Cancer Center and Y-mAbs Therapeutics, Inc., dated November 10, 2017 in its entirety, and such original Exhibit D is hereby cancelled and void.
SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
This Sponsored Research Agreement (this “Agreement”), effective as of the date of the last signature below (“Effective Date”), is between Memorial Sloan Kettering Cancer Center, a New York not-for-profit entity, with offices at 1275 York Avenue, New York, NY 10065 (“MSK”) and YmAbs, a Delaware corporation with a principal office at 750 Third Avenue, New York, NY 1017,(“Sponsor”). MSK and Sponsor may be individually referred to as a “Party”, and collectively as the “Parties”.
RXR HB OWNER LLC, Landlord TO Y-MABS THERAPEUTICS, INC., TenantLease • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
LEASE, dated as of January 10th, 2018, between RXR HB OWNER LLC (“Landlord”), a Delaware limited liability company whose address is c/o RXR Realty LLC, 625 RXR Plaza, Uniondale, NY 11556, and Y-MABS THERAPEUTICS, INC. (“Tenant”), a Delaware corporation, whose address is 750 Third Avenue, New York, New York 10017, prior to the commencement of the Term, and thereafter Tenant’s address shall be that of the Building.
SERVICE AGREEMENT BETWEEN Y-MABS THERAPEUTICS, INC. AND THOMAS GADService Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
FORM OF OFFICER AND DIRECTOR INDEMNIFICATION AGREEMENTOfficer and Director Indemnification Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • Delaware
OFFICER AND DIRECTOR INDEMNIFICATION AGREEMENT (the “Agreement”) dated as of [ ], 2017 by and between Y-MABS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·] (the “Indemnitee”).
SERVICE AGREEMENT BETWEEN Y-MABS THERAPEUTICS, INC. AND CLAUS JUAN MØLLER SAN PEDROService Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
Translation from Danish] LEASE AGREEMENT between Weco Management ApS Rungsted Strandvej 113Lease Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations
According to Appendix A of 30 May 2016, Weco Management ApS has leased a total of 1,591.90 square meters of the property SØHOLM, landmark no. 3-an and 3-oy., Rungsted Strandvej 113, 2960 Rungsted Kyst, Denmark (hereinafter referred to as the “Main Lease Agreement)
INVESTIGATOR-SPONSORED MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS INVESTIGATOR-SPONSORED TRIAL AGREEMENT (together with Appendix A, the “Agreement”) is made as of the date last signed below (the “Effective Date”) by and among Y-mAbs Therapeutics, Inc, a corporation with offices at 750 Third Avenue, 9th floor, New York, NY 10017 (“Company”), on the one hand; and MEMORIAL SLOAN KETTERING CANCER CENTER, a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, New York 10065, on behalf of Memorial Hospital for Cancer and Allied Diseases, its Regional Network sites, MSK Alliance Clinical Trial Sites, and its Cancer Health Equity Research Program Sites (“MSK”), and on behalf of itself and its employee specified in the applicable Study Addendum (“Investigator-Sponsor”), on the other hand. The parties agree that INVESTIGATOR-SPONSOR is not a party to this Agreement.
